index - Epidemiology in dermatology and evaluation of therapeutics

DOCUMENTS

98

 

NOTICES

156

 

 

MOTS CLES

Beta-lactam antibiotics Albinism Burden Vigibase® Bacterial Etanercept BTK protein Adverse side effects Pharmaco-Épidémiologie Pregnancy Ankylosing COVID-19 Management Adalimumab Bacterial rhinosinusitis Amyloidosis Biologic therapy Glucocorticoids Treatment Quality of life Spondylitis Intensive care Biological therapy Anti-HCV Direct Acting Antivirals DAA Ethics Primary adrenal insufficiency Graft-versus-host disease Stability Meta-Analysis Adolescent Immunotherapy Accelerometer Biologic Cardiomyopathy Cancer Immune checkpoint inhibitors Abus d'antibiotiques Dermatology Anxiety Axial spondyloarthritis Prostate cancer Apre-milast Autoimmunity Drug reaction Spondyloarthritis Pharmacovigilance Network meta-analysis Auto-immune hepatitis Acute Myeloid Leukaemia AML Anti-TNF Biologic drug Sacroiliitis Psoriasis Drug survival Placebo Biosimilar Pharmaceuticals Sipuleucel-T Antibiotic misuse Biomédicaments Atrial fibrillation Anti-Bacterial Agents Psoriatic arthritis Ankylosing spondylitis Antimicrobial Stewardship Biomarkers ASDAS Cardio-oncology Alitretinoin ArtThese Angiotensin-converting enzyme inhibitors Systematic review Biological Therapy Auto-Diagnostic Azathioprine Méta-Analyse Antimicrobials Arrhythmia Access to care Arthritis Infliximab Antimicrobial resistance Aging Autoimmune diseases Epidemiology Anxiété Endocrine toxicity Antibiotics Addiction Alcohol Atopic dermatitis Ustekinumab Apremilast Anticancer drugs Immune-related adverse events Antimicrobiens Antibiotic resistance Biologics Cardiotoxicity Angiotensin receptor blockers Pharmacoepidemiology

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS